摘要
目的 探讨喹硫平与氟哌啶醇治疗抽动障碍的临床疗效和安全性.方法 将90例抽动障碍患儿随机分为两组,研究组47例,口服喹硫平治疗,对照组43例,口服氟哌啶醇治疗,观察8周.于治疗前及治疗第2周、4周、8周末采用耶鲁抽动症严重程度量表及副反应量表评定临床疗效和不良反应.结果 两组治疗后耶鲁抽动症严重程度量表评分均呈持续性下降,但治疗8周末研究组较对照组下降更显著（P＜0.01）;研究组显效率为82.99%、对照组为62.79%,研究组显著高于对照组（χ2=4.680,P＜0.05）.研究组不良反应发生率为27.66%,对照组为81.40%,研究组显著低于对照组（χ2=26.052,P＜0.01）.结论 喹硫平与氟哌啶醇治疗儿童抽动障碍疗效均显著,但喹硫平疗效优于氟哌啶醇,且安全性更高,依从性更好.
Objective To explore the efficacy and safety of quetiapine vs. haloperidol in the treatment of childtic disorder. Methods Ninety-six children with tic disorder were randomly divided into research group （n=47） took orally quetiapine and control group （n =43） did haloperidol for 8 weeks. Clinical efficaies were assessed with the Yale Global Tic Severity Scale （YGTSS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the end of the 2nd, 4th and 8th week. Results After treatment, the YGTSS score of both groups lowered continuously,but at the end of the 8th week that did more significantly in the research than in the control group （P〈0.01）; the obvious effective rate was significantly higher in the research than in the control group （82.99% vs. 62.79%, x2 =4. 680,P〈0.05）. Incidences of adverse reactions were significantly lower in the research than in the control group （27.66% vs. 81.40, x2 =26. 052,P〈0.01）. Conclusion Both quetiapine and haloperidol are effective in child tic disorder, but quetispine has an advantage in efficacy, safety and compliance over haloperidol.
出处
《临床心身疾病杂志》
CAS
2011年第6期494-496,共3页
Journal of Clinical Psychosomatic Diseases
